Cargando…

Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF(V600E) Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report

A vast majority of colorectal cancer (CRC) patients with microsatellite stability (MSS) or proficient mismatch repair (pMMR) are refractory to immunotherapeutic strategies. The current research focusses on the combined treatment strategies for identification and optimization in order to improve the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Chongkai, Lin, Jietao, Zhang, Tao, Luo, Jiajun, Nie, Duorui, Li, Meng, Hu, Xue, Zheng, Yating, Huang, Xuewu, Xiao, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112237/ https://www.ncbi.nlm.nih.gov/pubmed/33987088 http://dx.doi.org/10.3389/fonc.2021.652394

Ejemplares similares

The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis
por: Fang, Chongkai, et al.
Publicado: (2022)

Microsatellite Stable Colorectal Cancers Stratified by the BRAF V600E Mutation Show Distinct Patterns of Chromosomal Instability
por: Bond, Catherine E., et al.
Publicado: (2014)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

VEGF blockade enhances the antitumor effect of BRAF(V) (600E) inhibition
por: Comunanza, Valentina, et al.
Publicado: (2016)

Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report
por: Tan, Li, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
por: Moschetta, Michele, et al.
Publicado: (2017)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy
por: Yao, Tsun-Wen, et al.
Publicado: (2015)

The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study
por: Duorui, Nie, et al.
Publicado: (2020)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature
por: Song, Minghan, et al.
Publicado: (2023)

Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer
por: Karki, Sophiya, et al.
Publicado: (2023)

Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study
por: Nie, Duorui, et al.
Publicado: (2022)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
por: Kanat, Ozkan, et al.
Publicado: (2020)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
por: Guerrero, Rodrigo Motta, et al.
Publicado: (2022)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
por: Randon, Giovanni, et al.
Publicado: (2023)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
por: Obasaju, Patience, et al.
Publicado: (2020)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Metastatic BRAF V600E-Mutated Adenocarcinoma of the Lung Presenting as Extreme Neutrophilia and Eosinophilia
por: Muhammad, Azharuddin, et al.
Publicado: (2021)

Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
por: Babačić, Haris, et al.
Publicado: (2021)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ih67j70deo0glh4v0cksf8gr1a